Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-09-01
2009-08-18
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S046000, C514S047000, C514S048000
Reexamination Certificate
active
07576068
ABSTRACT:
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.
REFERENCES:
patent: 4539205 (1985-09-01), Goodman et al.
patent: 4643992 (1987-02-01), Goodman et al.
patent: 4880784 (1989-11-01), Robins et al.
patent: 5011828 (1991-04-01), Goodman et al.
patent: 5041426 (1991-08-01), Robins et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5821236 (1998-10-01), Krenitsky et al.
patent: 5994321 (1999-11-01), Lewis et al.
patent: 6028076 (2000-02-01), Hirota et al.
patent: 6329381 (2001-12-01), Kurimoto et al.
patent: 6376501 (2002-04-01), Isobe et al.
patent: 2002/0173655 (2002-11-01), Dellaria et al.
patent: 2003/0065005 (2003-04-01), Charles et al.
patent: 2003/0100764 (2003-05-01), Bonk et al.
patent: 2003/0162806 (2003-08-01), Dellaria et al.
patent: 2003/0176458 (2003-09-01), Dellaria et al.
patent: 2003/0186949 (2003-10-01), Dellaria et al.
patent: 2003/0195209 (2003-10-01), Dellaria et al.
patent: 2003/0199461 (2003-10-01), Averett et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2005/0004144 (2005-01-01), Carson et al.
patent: 0 882 727 (1998-09-01), None
patent: 1 035 123 (2000-09-01), None
patent: 1 043 021 (2000-10-01), None
patent: 1 386 923 (2004-02-01), None
patent: WO-94/07904 (1994-04-01), None
patent: WO-94/17043 (1994-08-01), None
patent: WO-98/17279 (1998-04-01), None
patent: WO-03/045968 (2003-06-01), None
patent: WO 03/049670 (2003-06-01), None
Werner et al. Eur. J. Biochem. (1996), vol. 242, pp. 1-19.
Naylor et al. International Immunopharmacology (2003), vol. 3, pp. 1205-1215.
Pope et al. The Journal of Immunology (1993), vol. 151, pp. 3007-3017.
Lee et al. PNAS (2003), vol. 100, pp. 6646-6651.
Neumann et al. Science (1998), vol. 282, pp. 103-107.
Akira, “Mammalian Toll-like receptors”,Current Opinion, 2003, 15: 5-11.
Akira, “Toll-Like Receptor Signalling”,Immunology, 2004, 4:499-511.
Alexander et al., “(Acyloxy)alkyl Carbamates as Novel Bioreversible Prodrugs for Amines: Increased Permeation through Biological Membranes”, J. Med. Chem., 1988, 31:318-322.
Applequist et al., “Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines”,Int. Immunol., 2002, 14(9):1065-74.
Barrio et al., “Regioselective Fluorination of Substituted Guanines with Dilute F2: A Facile Entry to 8-Fluoroguanine Derivatives”,J. Org. Chem., 1996, 61:6084-6085.
Bottcher et al., “Differential regulation of Toll-like receptor mRNAs in experimental murine central nervous system infections”,Neurosci. Lett., 2003, 344(1):17-20.
Bruno et al., “Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8α+and CD8α−dendritic cells”,Eur. J. Immunol., 2001, 31(11):3403-12.
Chuang et al., “Cloning and characterization of a sub-family of human Toll-like receptors: hTLR7, hTLR8 and hTLR9”,Eur. Cytokine Netw., Sep. 2000, 11(3):372-8.
Diebold et al, “Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA”,Science, 2004, 303(5663):1481-2.
Doxsee et al, “The Immune Response Modifier and Toll-like Receptor 7 Agonist S-27609 Selectively Induces IL-12 and TNF-α Production in CD11c+CD11b+CD8−Dendritic Cells”,J. Immunol., 2003, 171(3):1156-63).
Du et al.,Eur. Cytokine Netw., 2000, 11(3), 362-71.
Edwards et al., “Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8α+DC correlates with unresponsiveness to imidazoquinolines”,Eur. J. Immunol., 2003, 33(4):827-33.
Fan et al., “Pyrimidines. 24. Analogues and Derivatives of 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP)”, J.Heterocyclic Chem., Nov. 1993, 30:1273-1276.
Fried, et al., “5-Substituted 2-Amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and Interferon- Inducing Agents”,J. Med. Chem., 1980, 23:237-239.
Fujiwara et al., “Synthesis and Bioactivities of Novel Piperidylpyrimidine Derivatives: Inhibitors of Tumor Necrosis Factor-Alpha Production”,Bioorg. Med. Chem. Lett., 2000, 10(12):1317-1320.
Furneaux et al., “Improved Syntheses of 3H,5H-Pyrrolo[3,2-d]pyrimidines”,J. Org. Chem., 64 (22), 8411-8412 (1999).
Gangwar et al., “Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug of a Hexapeptide Using an(Acyloxy)alkoxy Promoiety)”,J. Org. Chem., 1997, 62:1356-1362.
Gibson et al., “Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod”,Cell Immunol., 2002, 218(1-2):74-86.
Girgis et al., “Direct C-Flycosylation of Guanine Analogues: The Synthesis and Antiviral Activity of Certain 7- and 9-DeazaguanineC-Nucleosides”, J.Med. Chem., 1990, 33:2750-2755.
Heil et al., “The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily”,Eur. J. Immunol., 2003, 33(11):2987-97.
Hemmi et al., “Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway”,Nat. Immunol., 2002, 3(2):196-200.
Henry et al., “Synthesis and Broad-Spectrum Antiviral Activity of 7,8-Dihydro-7-methyl-8-thioxoguanosine”,J. Med. Chem., 1990, 33:2127-2130.
Hirota et al., “Discovery of 8-Hydroxyadenines as a Novel Type of Interferon Inducer”,J. Med. Chem., 2002, 45:5419-5422.
Horng et al., “The adaptor molecule TIRAP provides signaling specificity for Toll-like receptors”,Nature, 2002, 420(6913):329-333.
Hornung et al., “Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides”,J. Immunol., 2002, 168(9):4531-4537.
International Search Report (PCT/US2004/028236) dated Mar. 14, 2005.
Isobe et al, “Synthesis and Structure-Activity Relationships of 2-Substituted-8-hydroxyadenin Derivatives as Orally Available Interferon Inducers without Emetic Side Effects”,Bioorganic&Medicinal Chemistry, 2003, 11:3641-3647.
Ito et al., “Roles of Toll-Like Receptors in Natural Interferon-Producing Cells as Sensors in Immune Surveillance”,Hum. Immunol., 2002, 63(12):1120-1125.
Jarrossay, “Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells”,Eur. J. Immunol., 2001, 31(11):3388-3393.
Jurk et al., “Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848”,Nat. Immunol., 2002, 3(6):499.
Kerr et al, “Isatoribine, a Toll Like Receptor 7 Agonist, Significantly Reduced Plasma Viral Load in a Proof-of-Concept Study in Patients with Chronic Hepatitis C Virus Infection”, . . . .
Kini et al., “Synthesis and Antiviral Activity of Certain Guanosine Analogues in the Thiazolo[4,5-d]pyrimidine Ring System”,J. Med. Chem., 34:3006-3010.
Kurimoto et al., “Prodrugs of 9-Benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: Potent Interferon Inducing Agents in Monkeys”,Chem. Pharm. Bull., 2004, 52(4):466-469.
Kurimoto et al., “Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent inferferon inducers with improved oral bioavailabilities”,Bioorg. Med. Chem., 2004, 12:1091-1099.
Le Quesne et al., “Biomimetic Synthesis of Catechol Estrogens” Potentially Mutagenic Arene Oxide Intermediates in Estrogen Metabolism,J. Med. Chem, 1980, 2
Anadys Pharmaceuticals, Inc.
Connolly Bove & Lodge & Hutz LLP
Lewis Patrick T
LandOfFree
Administration of TLR7 ligands and prodrugs thereof for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of TLR7 ligands and prodrugs thereof for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of TLR7 ligands and prodrugs thereof for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110997